About OncoResponse
OncoResponse is a company based in Seattle (United States) founded in 2015 by Clifford J Stocks. OncoResponse has raised $149.62 million across 10 funding rounds from investors including ARE, Rice University and Takeda Pharmaceuticals. The company has 35 employees. OncoResponse offers products and services including Technology Platform and Monoclonal Antibodies. OncoResponse operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
- Headquarter Seattle, United States
- Employees 35
- Founders Clifford J Stocks
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website oncoresponse.com
- Social LinkedIn X
- Legal Name Oncoresponse, Inc.
- Total Equity Funding$149.62M (USD)
in 10 rounds
- Latest Funding Round$6M (USD), Series D
Apr 2025
- InvestorsARE
& 18 more
- Employee Count35
Products & Services of OncoResponse
OncoResponse offers a comprehensive portfolio of products and services, including Technology Platform and Monoclonal Antibodies.
Platform for discovering antibodies from elite responders.
Antibodies targeting immunosuppressive elements in tumors.
Funding Insights of OncoResponse
OncoResponse has successfully raised a total of $149.62M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $6 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $149.62M
- Total Rounds 10
- Last Round Series D — $6M
- First Round $9.5M
(Oct 2015)
- Investors Count 19
All 10 funding rounds of OncoResponse with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2025 | $6M | Series D | – | – | – |
| May 2023 | $13M | Grant | – | – | |
| May 2023 | $14M | Series D | – | RiverVest Venture Partners | |
| Feb 2022 | $50M | Debt – Conventional | – | – | |
| Mar 2021 | $40.63M | Series D | – | Yonjin Capital, RiverVest Venture Partners | – |
| Sep 2018 | $40M | Series C | – | RiverVest Venture Partners, Qatar Investment Authority | – |
| Mar 2017 | $29.5M | Series B | – | – | – |
| Oct 2016 | $7M | Series A | – | GreatPoint Ventures, 3B FUTURE Health Fund | – |
| May 2016 | $3M | Series A | – | Baxalta | – |
| Oct 2015 | $9.5M | Series A | – | Arch Venture Partners, Canaan | – |
19 investors in total: 19 institutional.
Investors in OncoResponse
OncoResponse has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Rice University and Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | rivervest.com | - | |
Early-stage healthcare investments are made by 3B Future Health Fund. | – | 3bfuturehealth.com | Luxembourg, Luxembourg | |
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Bering Capital is engaged in healthcare investment and company building. | – | beringcapital.com | San Francisco, United States | |
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Venture capital firm backed by Yongjin Group | – | yjventure.com | Cambridge, United States | |
Early-stage healthcare investments are made by this fund. | – | helsinninvestmentfund.com | Luxembourg, Luxembourg | |
Venture capital firm focused on early-stage big data, health tech, AI, food tech, and multiple sectors | – | gpv.com | San Francisco, United States | |
- | – | state.tx.us | - |
Investor details for OncoResponse
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OncoResponse
18 people are tracked at OncoResponse (4 in leadership, 14 in board & advisors); the tracked headcount is 35.
| Name | Role | Group |
|---|---|---|
Clifford J Stocks | Founder & CEO | Leadership |
Kamal D. Puri | Chief Scientific Officer | Leadership |
Chris Russell | Chief Financial Officer | Leadership |
Myriam Bouchlaka | Director Immuno-Oncology | Leadership |
Sean A. McCarthy | Director | Board & advisors |
Miriam Merad | Advisor | Board & advisors |
Mike Gallatin | Advisor | Board & advisors |
Wende Hutton | Director | Board & advisors |
Anil Singhal | Advisor | Board & advisors |
Michael A. Curran | Advisor | Board & advisors |
James W. Welsh | Advisor | Board & advisors |
David Hong | Advisor | Board & advisors |
Steven Gillis | Director | Board & advisors |
John McKearn | Director | Board & advisors |
Roberto De Ponti | Director | Board & advisors |
Ted Koutouzis | Director | Board & advisors |
David G. Denardo | Advisor | Board & advisors |
Carol Gallagher | Independent Director | Board & advisors |
Complete people profiles for OncoResponse
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OncoResponse
3 dated milestones of OncoResponse across 10 years, from founding to its latest funding, stage changes and deals.
- Founded OncoResponse is founded.
- Funding First funding round of $9.5M.
- Funding Latest funding round, Series D, of $6.0M.
Competitors of OncoResponse
OncoResponse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Regeneron Pharmaceuticals and MorphoSys, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| regeneron.com | 1988 | Tarrytown, United States | – | 13,450 | Antibodies are developed for treating cancer, eye, and inflammatory diseases. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. | |
| ventyxbio.com | 2018 | Encinitas, United States | $165.3M | 79 | Therapeutics for autoimmune diseases are developed by the company. | |
| ascendispharma.com | 2007 | Hellerup, Denmark | $108.7M | 573 | Long-acting prodrug therapies are developed for endocrine and rare diseases. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders |
Detailed competitors of OncoResponse
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncoresponse
Complete news archive for OncoResponse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OncoResponse
10 companies that operate in the same segment as OncoResponse (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OncoResponse
OncoResponse was founded in 2015.
OncoResponse is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Clifford J Stocks is the current CEO of OncoResponse. They have also founded this company.
OncoResponse is a funded company, having raised a total of $149.62M across 10 funding rounds to date. The company's 1st funding round was a Series A of $9.5M, raised on Oct 2015.
OncoResponse has 35 employees.
OncoResponse was founded in 2015 and is headquartered in Seattle, United States. Focus is placed on the biotechnology sector, where immunotherapies for cancer are advanced through a proprietary technology platform. Human antibodies are discovered, and an immune checkpoint inhibitor is developed. The lead candidate, OR2805, targets multiple tumor types. Operations emphasize research and development in oncology.
OncoResponse's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
OncoResponse offers Technology Platform and Monoclonal Antibodies.
OncoResponse has 19 investors. Key investors include ARE, Rice University, Takeda Pharmaceuticals, Oxford Finance, and Arch Venture Partners.
OncoResponse operates through Oncoresponse, Inc..